Therefore, in this study, we investigated RasGRF1 levels after CCH to explore the underlying mechanisms of CCH-induced cognitive impairment and to determine new effective therapeutic targets. This evidence concerns the gene RASGRF1 and columnar cell hyperplasia of the breast.